Logo image of VRAY

VIEWRAY INC (VRAY) Stock Fundamental Analysis

NASDAQ:VRAY - Nasdaq - US92672L1070 - Common Stock - Currency: USD

0.025  -0.02 (-39.9%)

After market: 0.0251 +0 (+0.4%)

Fundamental Rating

2

Overall VRAY gets a fundamental rating of 2 out of 10. We evaluated VRAY against 191 industry peers in the Health Care Equipment & Supplies industry. VRAY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VRAY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VRAY has reported negative net income.
VRAY had a negative operating cash flow in the past year.
In the past 5 years VRAY always reported negative net income.
In the past 5 years VRAY always reported negative operating cash flow.
VRAY Yearly Net Income VS EBIT VS OCF VS FCFVRAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

VRAY has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRAY Yearly ROA, ROE, ROICVRAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K

1.3 Margins

Looking at the Gross Margin, with a value of 8.05%, VRAY is doing worse than 85.00% of the companies in the same industry.
VRAY's Gross Margin has declined in the last couple of years.
VRAY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 8.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-11.97%
VRAY Yearly Profit, Operating, Gross MarginsVRAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

VRAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VRAY has been increased compared to 1 year ago.
Compared to 1 year ago, VRAY has a worse debt to assets ratio.
VRAY Yearly Shares OutstandingVRAY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M
VRAY Yearly Total Debt VS Total AssetsVRAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

VRAY has an Altman-Z score of -6.16. This is a bad value and indicates that VRAY is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.16, VRAY is not doing good in the industry: 72.00% of the companies in the same industry are doing better.
VRAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.16
ROIC/WACCN/A
WACC6.05%
VRAY Yearly LT Debt VS Equity VS FCFVRAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

VRAY has a Current Ratio of 1.16. This is a normal value and indicates that VRAY is financially healthy and should not expect problems in meeting its short term obligations.
VRAY has a Current ratio of 1.16. This is amonst the worse of the industry: VRAY underperforms 91.00% of its industry peers.
VRAY has a Quick Ratio of 1.16. This is a bad value and indicates that VRAY is not financially healthy enough and could expect problems in meeting its short term obligations.
VRAY's Quick ratio of 0.86 is on the low side compared to the rest of the industry. VRAY is outperformed by 90.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 0.86
VRAY Yearly Current Assets VS Current LiabilitesVRAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

VRAY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.25%.
VRAY shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.09%.
The Revenue has been growing by 24.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)44.09%
Revenue growth 3Y5.2%
Revenue growth 5Y24.59%
Sales Q2Q%19.38%

3.2 Future

VRAY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.77% yearly.
Based on estimates for the next years, VRAY will show a quite strong growth in Revenue. The Revenue will grow by 18.71% on average per year.
EPS Next Y12.95%
EPS Next 2Y18.04%
EPS Next 3Y15.77%
EPS Next 5YN/A
Revenue Next Year-9.41%
Revenue Next 2Y11.46%
Revenue Next 3Y18.71%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
VRAY Yearly Revenue VS EstimatesVRAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
VRAY Yearly EPS VS EstimatesVRAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VRAY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRAY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRAY Price Earnings VS Forward Price EarningsVRAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRAY Per share dataVRAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

VRAY's earnings are expected to grow with 15.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.04%
EPS Next 3Y15.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRAY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIEWRAY INC

NASDAQ:VRAY (7/25/2023, 8:15:48 PM)

After market: 0.0251 +0 (+0.4%)

0.025

-0.02 (-39.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-03 2023-08-03/amc
Earnings (Next)10-30 2023-10-30/amc
Inst Owners0.2%
Inst Owner Change0%
Ins Owners17.32%
Ins Owner Change0%
Market Cap4.58M
Analysts73.33
Price Target1.22 (4780%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.72%
Min EPS beat(2)0.18%
Max EPS beat(2)7.26%
EPS beat(4)4
Avg EPS beat(4)2%
Min EPS beat(4)0.05%
Max EPS beat(4)7.26%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-2.26%
Max Revenue beat(2)0.34%
Revenue beat(4)3
Avg Revenue beat(4)3.66%
Min Revenue beat(4)-2.26%
Max Revenue beat(4)12.76%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-63.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.11%
EPS NY rev (1m)14.95%
EPS NY rev (3m)14.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-17.24%
Revenue NY rev (1m)-20.3%
Revenue NY rev (3m)-20.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.08
P/tB 0.08
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.58
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 8.05%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-11.97%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 0.86
Altman-Z -6.16
F-Score3
WACC6.05%
ROIC/WACCN/A
Cap/Depr(3y)67.17%
Cap/Depr(5y)94.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y12.95%
EPS Next 2Y18.04%
EPS Next 3Y15.77%
EPS Next 5YN/A
Revenue 1Y (TTM)44.09%
Revenue growth 3Y5.2%
Revenue growth 5Y24.59%
Sales Q2Q%19.38%
Revenue Next Year-9.41%
Revenue Next 2Y11.46%
Revenue Next 3Y18.71%
Revenue Next 5YN/A
EBIT growth 1Y-0.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.44%
EBIT Next 3Y15.77%
EBIT Next 5YN/A
FCF growth 1Y-91.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-106.14%
OCF growth 3YN/A
OCF growth 5YN/A